EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska-Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica iD, Anna Mrozek-Wilczkiewicz, Katarzyna Malarz iD

Molecular Oncology · 2026-11 · 20 (11) · 2741-2763

DOI: 10.1002/1878-0261.70274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 27.05.2026. Verfasst von Patryk Rurka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physics, University of Silesia in Katowice, Chorzów, Poland. Hauptthemen laut MEDLINE: Glioblastoma, Quinazolinones, Glucose, Receptor, Insulin. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant signaling through insulin‐like growth factor 1 receptor (IGF1R) and epidermal growth factor receptor (EGFR) drives glioblastoma (GBM) progression and therapy resistance. Herein, we describe the synthesis and biological evaluation of W1B, a novel styrylquinazolinone‐based small‐molecule inhibitor. In antiproliferative assays, W1B exhibited potent submicromolar activity against a panel of GBM cell lines. Kinase assays and binding studies confirmed strong inhibition and high binding affinity toward IGF1R. Molecular docking suggested possible interactions with both IGF1R and EGFR, with W1B adopting distinct binding poses in each kinase domain. In cellular studies, W1B reduced IGF1R and EGFR protein levels in LN229 cells and suppressed Akt phosphorylation. Under high‐glucose conditions, however, W1B only retained inhibitory activity toward IGF1R, resulting in attenuated effects on the Akt/mTOR axis and underscoring the influence of glucose‐dependent signaling rewiring on drug efficacy. Combination studies revealed that W1B acts synergistically with the EGFR inhibitor dacomitinib, effectively overcoming compensatory activation of parallel pathways. Biomimetic lipophilicity and in silico pharmacokinetic analyses indicated that styrylquinazolinone has the potential to cross the blood–brain barrier (BBB). The in vivo studies on Danio rerio have shown a good safety profile, as well as strong antitumor potential of the tested compound. Therefore, these findings establish W1B as a promising derivative for the development of next‐generation dual IGF1R/EGFR inhibitors in GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaQuinazolinonesGlucoseReceptor, InsulinProtein Kinase InhibitorsBrain NeoplasmsHumansErbB ReceptorsAnimalsCell Line, TumorMolecular Docking SimulationDrug SynergismZebrafishCell ProliferationSignal TransductionReceptor, IGF Type 1Antineoplastic Agents

Stichwörter der Autor:innen

EGFRIGF1R kinaseanticancer activitycombination therapyglioblastomainsulin inhibitorstyrylquinazolinone

Substanzen

ErbB ReceptorsQuinazolinonesGlucoseReceptor, InsulinProtein Kinase InhibitorsReceptor, IGF Type 1EGFR protein, humanAntineoplastic AgentsdacomitinibIGF1R protein, human

Autor:innen und Institutionen

  • Institute of Physics, University of Silesia in Katowice, Chorzów, Poland.
  • Institute of Chemistry, University of Silesia in Katowice, Chorzów, Poland.
  • Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Kraków, Poland.
  • Department of Biopharmacy, Medical University of Lublin, Poland.
  • Department of Physical Chemistry, Institute of Chemical Sciences, Maria Curie-Skłodowska University in Lublin, Poland.
  • Department of Medical Chemistry, Medical University of Lublin, Poland.

ORCID-Profile: Mateusz Jasica, Katarzyna Malarz

Förderung

  • Narodowe Centrum Nauki

Zitieren

APA

Rurka, P., Cieślik, W., Płaziński, W., Stępnik, K., Boguszewska-Czubara, A., Kot, E., Musioł, R., Jasica, M., Mrozek-Wilczkiewicz, A., & Malarz, K. (2026). A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma. Molecular Oncology, 20(11), 2741-2763. https://doi.org/10.1002/1878-0261.70274

Vancouver

Rurka P, Cieślik W, Płaziński W, Stępnik K, Boguszewska-Czubara A, Kot E, et al. A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma. Molecular Oncology. 2026;20(11):2741-2763. doi:10.1002/1878-0261.70274

BibTeX
@article{Rurka2026,
  author = {Rurka, Patryk and Cieślik, Wioleta and Płaziński, Wojciech and Stępnik, Katarzyna and Boguszewska-Czubara, Anna and Kot, Elżbieta and Musioł, Robert and Jasica, Mateusz and Mrozek-Wilczkiewicz, Anna and Malarz, Katarzyna},
  title = {A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {11},
  pages = {2741--2763},
  doi = {10.1002/1878-0261.70274}
}
Kostenlos starten →